Maravai Lifesciences Holdings (MRVI) Stock Forecast & Price Target

Compare

411 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRVI Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Maravai

Lifesciences Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRVI Stock 12 Month Forecast

Average Price Target

$4.25

▲(9.54% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Maravai Lifesciences Holdings in the last 3 months. The average price target is $4.25 with a high forecast of $4.50 and a low forecast of $4.00. The average price target represents a 9.54% change from the last price of $3.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","2.25":"$2.25","3.5":"$3.5","4.75":"$4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.25,3.3461538461538463,3.4423076923076925,3.5384615384615383,3.6346153846153846,3.730769230769231,3.826923076923077,3.9230769230769234,4.019230769230769,4.115384615384615,4.211538461538462,4.3076923076923075,4.403846153846154,{"y":4.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.25,3.326923076923077,3.4038461538461537,3.480769230769231,3.5576923076923075,3.6346153846153846,3.7115384615384617,3.7884615384615383,3.8653846153846154,3.9423076923076925,4.019230769230769,4.096153846153847,4.173076923076923,{"y":4.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.25,3.3076923076923075,3.3653846153846154,3.423076923076923,3.480769230769231,3.5384615384615383,3.5961538461538463,3.6538461538461537,3.7115384615384617,3.769230769230769,3.826923076923077,3.8846153846153846,3.9423076923076925,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$4.50

Average Price Target$4.25

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Hewitt

Craig-Hallum

Buy

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Maravai Lifesciences Holdings (NASDAQ: MRVI)

Brandon Couillard

Wells Fargo

$4→$4.5

Buy

15.98%

Upside

Reiterated

12/15/25

Maravai Lifesciences price target raised to $4.50 from $4 at Wells FargoMaravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo

Daniel Arias

Stifel Nicolaus

$5→$4

Buy

3.09%

Upside

Reiterated

11/07/25

Maravai Lifesciences Holdings (MRVI) Receives a Buy from Stifel Nicolaus

Matt Larew

William Blair

Hold

―

Assigned

11/07/25

Cautious Optimism for Maravai Lifesciences: Hold Rating Amidst Strategic Recovery Efforts

Conor McNamara

RBC Capital

Buy

28.87%

Upside

Reiterated

09/02/25

RBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

Hold

―

Reiterated

08/11/25

Maravai Lifesciences Holdings (MRVI) Gets a Hold from Guggenheim

Tejas Savant

Morgan Stanley

Hold

28.87%

Upside

Reiterated

05/21/25

Hold Rating for Maravai Lifesciences Holdings Amid Revenue Challenges and Uncertainty in CleanCap Orders

Catherine Ramsey Schulte

Robert W. Baird

$3→$2

Hold

-48.45%

Downside

Reiterated

05/13/25

Maravai Lifesciences price target lowered to $2 from $3 at BairdMaravai Lifesciences price target lowered to $2 from $3 at Baird

John Sourbeer

UBS

$8→$2.5

Hold

-35.57%

Downside

Reiterated

03/21/25

Maravai LifeScience Holdings Inc. (MRVI) PT Lowered to $2.50 at UBSUBS analyst John Sourbeer lowered the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $2.50 (from $8.00) while maintaining a Neutral rating.

Matthew Stanton, CFA

Jefferies

$10

Buy

157.73%

Upside

Reiterated

03/18/25

Buy Rating for Maravai Lifesciences Holdings: Strategic Financial Decisions and Growth Potential Amidst Challenges

Michael Ryskin

Bank of America Securities

$9→$8

Buy

106.19%

Upside

Reiterated

03/03/25

Bank of America Securities Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Hewitt

Craig-Hallum

Buy

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Maravai Lifesciences Holdings (NASDAQ: MRVI)

Brandon Couillard

Wells Fargo

$4→$4.5

Buy

15.98%

Upside

Reiterated

12/15/25

Maravai Lifesciences price target raised to $4.50 from $4 at Wells FargoMaravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo

Daniel Arias

Stifel Nicolaus

$5→$4

Buy

3.09%

Upside

Reiterated

11/07/25

Maravai Lifesciences Holdings (MRVI) Receives a Buy from Stifel Nicolaus

Matt Larew

William Blair

Hold

―

Assigned

11/07/25

Cautious Optimism for Maravai Lifesciences: Hold Rating Amidst Strategic Recovery Efforts

Conor McNamara

RBC Capital

Buy

28.87%

Upside

Reiterated

09/02/25

RBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

Hold

―

Reiterated

08/11/25

Maravai Lifesciences Holdings (MRVI) Gets a Hold from Guggenheim

Tejas Savant

Morgan Stanley

Hold

28.87%

Upside

Reiterated

05/21/25

Hold Rating for Maravai Lifesciences Holdings Amid Revenue Challenges and Uncertainty in CleanCap Orders

Catherine Ramsey Schulte

Robert W. Baird

$3→$2

Hold

-48.45%

Downside

Reiterated

05/13/25

Maravai Lifesciences price target lowered to $2 from $3 at BairdMaravai Lifesciences price target lowered to $2 from $3 at Baird

John Sourbeer

UBS

$8→$2.5

Hold

-35.57%

Downside

Reiterated

03/21/25

Matthew Stanton, CFA

Jefferies

$10

Buy

157.73%

Upside

Reiterated

03/18/25

Buy Rating for Maravai Lifesciences Holdings: Strategic Financial Decisions and Growth Potential Amidst Challenges

Michael Ryskin

Bank of America Securities

$9→$8

Buy

106.19%

Upside

Reiterated

03/03/25

Bank of America Securities Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Maravai Lifesciences Holdings

1 Month

xxx

Success Rate

9/15 ratings generated profit

Average Return

+2.79%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +2.79% per trade.

3 Months

xxx

Success Rate

8/17 ratings generated profit

Average Return

-2.64%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -2.64% per trade.

1 Year

Matt HewittCraig-Hallum

Success Rate

8/15 ratings generated profit

Average Return

-0.43%

reiterated a buy rating 3 days ago

Copying Matt Hewitt's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of -0.43% per trade.

2 Years

xxx

Success Rate

8/15 ratings generated profit

Average Return

+5.37%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of +5.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRVI Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRVI has received 7 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. MRVI average Analyst price target in the past 3 months is 4.25.

Each month's total comprises the sum of three months' worth of ratings.

MRVI Financial Forecast

MRVI Earnings Forecast

Next quarter’s earnings estimate for MRVI is -$0.07 with a range of -$0.10 to -$0.06. The previous quarter’s EPS was -$0.08. MRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.

MRVI Sales Forecast

Next quarter’s sales forecast for MRVI is $49.05M with a range of $48.75M to $49.60M. The previous quarter’s sales results were $41.63M. MRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.

MRVI Stock Forecast FAQ

What is MRVI’s average 12-month price target, according to analysts?

Based on analyst ratings, Maravai Lifesciences Holdings’s 12-month average price target is 4.25.

What is MRVI’s upside potential, based on the analysts’ average price target?

Maravai Lifesciences Holdings has 9.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRVI a Buy, Sell or Hold?

Maravai Lifesciences Holdings has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is Maravai Lifesciences Holdings’s price target?

The average price target for Maravai Lifesciences Holdings is 4.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $4.50 ,the lowest forecast is $4.00. The average price target represents 9.54% Increase from the current price of $3.88.

What do analysts say about Maravai Lifesciences Holdings?

Maravai Lifesciences Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of MRVI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Maravai Lifesciences Holdings (MRVI) Stock Forecast & Price Target

MRVI Analyst Ratings

MRVI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Maravai Lifesciences Holdings

MRVI Analyst Recommendation Trends

MRVI Financial Forecast

MRVI Earnings Forecast

MRVI Sales Forecast

MRVI Stock Forecast FAQ

Detailed List of Analyst Forecasts